DorsaVi’s Revenue Falls 14%, Loss Widens to $1.52M in FY25
DorsaVi Limited reported a 13.9% revenue decline and a 21.7% rise in net loss for FY25, while securing over $3 million in capital to fuel new technology ventures.
- Revenue down 13.9% to $1.15 million
- Net loss increased 21.7% to $1.52 million
- Net assets surged to $2.84 million following capital raises
- No dividends declared or paid during FY25
- Post-year $5 million placement announced for RRAM and Robotics development
Financial Performance Highlights
DorsaVi Limited, a healthcare technology company specialising in medical devices and wearables, has reported its preliminary financial results for the year ended 30 June 2025. The company experienced a 13.9% decline in revenues, falling to approximately $1.15 million from $1.34 million the previous year. This revenue contraction was accompanied by a 21.7% increase in net loss after tax, which widened to $1.52 million.
Despite the increased loss, operating expenses remained broadly consistent with the prior year, indicating that the company managed to control costs amid challenging revenue conditions. The loss reflects ongoing investments in research and development, particularly in emerging technologies.
Balance Sheet and Capital Raising
On the balance sheet front, DorsaVi’s net assets saw a significant uplift, rising from $1.02 million to $2.84 million. This improvement was largely driven by successful capital raisings exceeding $3 million during the financial year. The fresh capital injection has bolstered the company’s cash position, providing a stronger financial foundation to support its strategic initiatives.
Notably, the company did not declare or pay any dividends during the year, signalling a focus on reinvestment rather than shareholder returns at this stage.
Strategic Outlook and Leadership Changes
Post-year-end developments include a $5 million placement aimed at accelerating the development of DorsaVi’s RRAM and Robotics technology platforms. This move underscores the company’s commitment to innovation and expanding its technological capabilities within the healthcare sector.
Additionally, DorsaVi announced the appointment of Mathew Regan as Group Executive Officer, effective 1 November 2025. Regan’s leadership is expected to play a pivotal role in steering the company through its next growth phase, supported by performance rights that align his incentives with shareholder value creation.
Technology and Market Position
DorsaVi continues to invest heavily in patents and intangible assets, reflecting its strategy to maintain a competitive edge in medical wearables and diagnostic technology. The company’s focus on RRAM and Robotics signals an ambition to leverage cutting-edge innovations to capture new market opportunities.
While the revenue decline and increased losses highlight near-term challenges, the strengthened balance sheet and strategic capital raises position DorsaVi to pursue growth and technological advancement with renewed vigour.
Bottom Line?
DorsaVi’s FY25 results reveal short-term pressures but a clear strategic pivot backed by fresh capital and leadership renewal.
Questions in the middle?
- How will the $5 million placement impact shareholder dilution and future earnings?
- What milestones are targeted for the RRAM and Robotics technology development?
- How will new leadership influence operational efficiency and commercial traction?
